Clinical Context
A newborn infant in the neonatal intensive care unit (NICU) born to a mother with a positive cytomegalovirus (CMV) serology during pregnancy is evaluated for congenital infection. The infant presents with jaundice, petechiae, and low birth weight within the first week of life. A buccal swab or urine specimen is collected and sent to the hospital molecular diagnostics laboratory for nucleic acid amplification testing (NAAT) specific for CMV. The lab analyst performs 87496 using an amplified nucleic acid probe technique to detect CMV DNA or RNA. Results are reported to the neonatologist and infectious disease consultant; positive NAAT within the first 3 weeks of life supports congenital CMV and guides antiviral management and further audiology and neuroimaging evaluations.
Typical workflow:
-
Clinical team orders CMV NAAT (87496) with specimen type and collection time noted.
-
Specimen labeled and transported to molecular lab with chain-of-custody and accessioning.
-
Laboratory technologist/analyst performs specimen processing, nucleic acid extraction, amplification and probe-based detection per assay protocol.
-
Results reviewed by lab director or qualified technologist; positive/negative and semi-quantitative data (if available) are entered into the electronic medical record.
-
Result communicated to ordering clinician; result may prompt confirmatory testing, initiation of antiviral therapy in symptomatic neonates or immunocompromised adults, and public health or perinatal follow-up.
Coding Specifications
| Modifier | Description | When to Use |
|---|
26 | Professional component | Use when billing only the professional interpretation/read of the test if facility separates technical and professional components. |
| 59 | Distinct procedural service | Use when this test is distinct and separate from other procedures on the same day (e.g., distinct specimen testing).
| 90 | Reference (outside) laboratory | Use when the specimen is sent to an outside independent laboratory for testing.
| 91 | Repeat clinical diagnostic laboratory test | Use when the same test is repeated on the same patient to obtain subsequent results for monitoring or verification.
| 52 | Reduced services | Use when the test is partially reduced or not performed to full definition of the CPT code.
| 22 | Increased procedural services | Use when the service requires substantially greater resources than typical; must be documented.
| 59 | Distinct procedural service | Use when the laboratory test is distinct from other services provided the same day (maintained here due to high clinical relevance).
| 90 | Reference (outside) laboratory | Use when specimen processing or testing is performed entirely by an outside reference lab (duplicate due to high relevance).
| 91 | Repeat clinical diagnostic laboratory test | Use for repeats due to monitoring or discrepant results (duplicate due to high relevance).
| 95 | Synchronous telemedicine service rendered via real-time interactive audio and video | Rarely used for lab testing but applicable if test result review or consultation is performed via telemedicine by the ordering provider.
| Taxonomy Code | Specialty | Notes |
|---|
| 207Q00000X | Clinical Laboratory | Laboratory directors and molecular diagnosticians performing NAAT. |
| 207L00000X | Pathology | Pathologists supervising molecular testing and result interpretation.
| 208000000X | Pediatrics | Neonatologists ordering CMV testing in infants.
| 207P00000X | Infectious Disease | ID specialists managing CMV in immunocompromised patients.
| 2086S0126X | Obstetrics & Gynecology | Maternal-fetal medicine providers ordering prenatal CMV evaluation.
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|
P35.1 | Congenital cytomegalovirus infection | Primary diagnosis for newborns tested with 87496 to confirm congenital CMV. |
| B25.9 | Cytomegaloviral disease, unspecified | CMV disease in immunocompromised patients where NAAT is used to detect active infection.
| P37.9 | Neonatal infection, unspecified | Used when a neonate has signs of infection and CMV testing is part of the diagnostic workup.
| Z38.00 | Single liveborn infant, delivered in hospital, born in hospital | Contextual birth code often present on newborn test orders and claims.
| Z21 | Asymptomatic human immunodeficiency virus [HIV] infection status | HIV-positive status in the mother or infant increases CMV risk and may prompt CMV NAAT.
| A54.02 | Gonococcal infection of newborn, conjunctival | Example of other neonatal infections often evaluated concurrently; included for clinical workflow relevance.
| R68.89 | Other general symptoms and signs | Non-specific neonatal symptoms (jaundice, poor feeding) prompting broad infectious testing including CMV.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|
87496 | Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus (CMV), amplified probe technique | Primary test performed for direct detection of CMV nucleic acid using amplified probe methods. |
| 87491 | Infectious agent detection by nucleic acid (DNA or RNA); adenovirus, amplified probe technique | Other viral NAATs that may be ordered in differential viral workups when evaluating neonatal or immunocompromised patients.
| 87661 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory syncytial virus (RSV), amplified probe technique | Respiratory viral NAAT commonly performed alongside CMV in infants with respiratory symptoms.
| 87340 | Infectious agent antigen detection by immunoassay technique, multiple-step method; cytomegalovirus (CMV) | Alternative CMV testing modality (antigen detection) that may be used in certain clinical workflows.
| 87489 | Infectious agent detection by nucleic acid (DNA or RNA); other virus, amplified probe technique, each organism | Used when additional or multiplex viral NAATs are performed on the same specimen or cohort of tests.
| 87497 | Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus (CMV), amplified probe technique, quantitative | Quantitative CMV NAAT that may be ordered when viral load monitoring is required in immunocompromised patients.